Affimed CEO to Present at the Jefferies 2015 Global Healthcare Conference – London

Press Release - November 11, 2015

Download Press Release

Heidelberg,  Germany,  November  11,  2015  –  Affimed  N.V.  (Nasdaq:  AFMD)  today  announced that Dr. Adi Hoess, CEO, will present a corporate overview at the Jefferies Autumn  2015  Global  Healthcare  Conference  –  London,  to  be  held  November  18-­19,  2015. In addition, Dr. Hoess has been invited to participate in Jefferies’ panel discussion titled “Biotech Financing -­ Finding the Right Investor Base, US vs. Europe” to outline and discuss Affimed’s listing venue decision as an EU-­based company listing on the Nasdaq.

Panel Discussion
Wednesday, November 18, at 12:20 p.m. (GMT)

Corporate Overview Presentation
Wednesday, November 18, 1:20-­2:00 p.m. (GMT)

To access a simultaneous webcast of Dr. Hoess’ corporate overview presentation online, log  on  to http://wsw.com/webcast/jeff92/afmd  or  go  to  the Webcast section on the Affimed website.

A replay of the webcast will be available from Affimed’s website for 30 days following the conference.  Dr.  Hoess’  presentation  will  be  available  for  download  in  PDF  format  immediately following the conference presentation.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.

Affimed IR Contact

Caroline Stewart, Head IR & Communication Phone: +1 347 394 6793
E-Mail: email hidden; JavaScript is required or email hidden; JavaScript is required

Media Requests

Stephanie May or Gretchen Schweitzer
MacDougall Biomedical Communications
Phone: +49 89 2424 3494 or +49 172 861 8540
E-Mail: email hidden; JavaScript is required

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.

Okay